Ropes & Gray advised Novo Nordisk in a partnership agreement with Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated diseases in oral formulations. The transaction was announced on February 25.
Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, and Vivtex is eligible to receive upfront consideration, research funding and milestone payments for up to $2.1 billion, and tiered royalties on future product sales. Following research and formulation selection, Novo Nordisk would assume responsibility for global development, regulatory activities, manufacturing and commercialization of any resulting products.
The collaboration is designed to allow for oral delivery of biologic drug candidates that are traditionally limited to injectable administration due to poor gastrointestinal absorption. The partnership combines Novo Nordisk’s expertise in peptide and protein therapeutics with Vivtex’s proprietary gastrointestinal screening and formulation platform.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associate Ian Nilsen.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.